Melanoma Treatment Market 2021-2028: Know Opportunities, Risks, Driving Factors, Vendors, Regions

The American Cancer Society's estimates for melanoma in the United States for 2021 are: About 106,110 new melanomas will be diagnosed (about 62,260 in men and 43,850 in women). About 7,180 people are expected to die of melanoma (about 4,600 men and 2,580 women). Such a high prevalence of melanoma is propelling the growth of the melanoma treatment market. Moreover, the advent of new drugs is again expected to fuel the growth of the market. For instance, in July 2020, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/719

North America is expected to lead the global melanoma treatment market owing to the increasing number of research & development programs in the region. For instance, in April 2021, Cannabics Pharmaceuticals Inc. a global marketer in the development of cancer-related cannabinoid-based medicine, announced the launching of a new research program for the development of a Melanoma antitumor targeting medicine

In July 2020, Roche announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) plus Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients

In June 2021, BioNTech SE announced that the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial (2020-002195-12; NCT04526899). The study is evaluating the Company’s therapeutic cancer vaccine candidate BNT111 in combination with Libtayo® (cemiplimab) in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma

In February 2021, the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo® (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate.

Melanin is a pigment to be found in the skin's surface, primarily in the hair follicles, where it provides the brown pigment. When the skin gets damaged from frequent sun exposure, melanoma grows on the parts of exposed skin wherein the greatest level of sunlight has been received. Melanoma of the face and head is fatal cancer that arises from melanocytes (cells that give skin its pigmentation or coloring) which may be benign or malignant. Melanoma is the second leading cause of mortality in the United States, following only skin cancer.

Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Genetech Inc., AstraZeneca, Novartis AG, Polynoma LLC, Amgen Inc., Merck & Co. Inc., Sanofi, and Takeda Pharmaceutical Company are some of the key players in the market

Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/719

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.